If you or someone you love has been battling lichen Sclerosus (LS), you know how stubborn and life-altering this condition can be. You might have tried every cream and treatment in the book by now. Still, the itching, the pain, and the skin changes persist. But imagine a therapy that not only calms the inflammation but also helps regenerate healthy skin. Enter Mesenchymal Stem Cell (MSC) therapy — particularly MSCs sourced from an unexpected place: Wharton’s Jelly of the umbilical cord. Continuing our exploration of MSC therapy for LS, we’ll dive into what makes Wharton’s Jelly-derived MSCs (WJ-MSCs) unique and why combining them with platelet-rich plasma (PRP) could be a game-changer.
The Unique Advantages of Wharton’s Jelly MSCs
Wharton’s Jelly is the gelatinous cushioning tissue in the umbilical cord that protects blood vessels. It turns out this jelly is a goldmine of potent MSCs. What’s unique about these cells compared to stem cells from other sources (like your own fat or bone marrow)? Let’s break it down:
- Easy, Non-Invasive Sourcing: Getting MSCs from Wharton’s Jelly doesn’t require any surgery or needles for the patient. The umbilical cord is typically discarded after birth, so harvesting its stem cells poses no harm or invasive procedure to the donor. In contrast, bone marrow MSCs need a painful extraction from the hip bone pmc.ncbi.nlm.nih.gov, and adipose (fat) MSCs require liposuction. WJ-MSCs come from a readily available and ethical source — essentially medical waste turned into a healing resource.
- Youthful and Highly Potent: WJ-MSCs are newborn cells — literally. They come from a neonatal tissue protected from aging and environmental damage. Think of them as “young” stem cells with their life ahead. Because of this youthful phenotype, they have rapid proliferation and growth capacity. Studies show WJ-MSCs can often multiply faster and longer than adult MSCs from bone marrow or fat. They haven’t been exposed to decades of stress or toxins, which may make them more uniform and stable in therapy. This means a single donated umbilical cord can yield a robust supply of MSCs to treat many patients or multiple areas.
- Immuno-Privileged and Allogeneic Use: One of the most remarkable perks of WJ-MSCs is that they are naturally immunomodulatory and hypoimmunogenic. These cells express very low levels of the “ID tags” that typically make donated tissue rejectable by the immune system — for example, they lack HLA-DR (MHC class II) and have high levels of immunosuppressive molecules like HLA-G and PGE2 (pmc. ncbi.nlm.nih.gov. In plain language: WJ-MSCs can often be given to a patient who is not the donor without causing an immune attack. They play nice with the recipient’s immune system. This is a big differentiator from other stem cell sources. Bone marrow or adipose stem cells are usually taken from your body to avoid rejection. WJ-MSCs, however, can be prepared “off the shelf” from screened, healthy donors—no need for you to undergo a procedure to harvest your cells. The donated WJ-MSCs are ready to use and well-tolerated in the body pmc.ncbi.nlm.nih.gov.
- Potent Immunomodulators: WJ-MSCs aren’t just less likely to cause immune reactions — they actively calm harmful inflammation. These cells secrete beneficial proteins that can dial down overactive immune responses. For instance, WJ-MSCs naturally produce factors like indoleamine-2,3-dioxygenase (IDO) and PGE2 that suppress inflammatory T-cells and encourage a more regulated immune environment. They’ve been used successfully in autoimmune conditions and even graft vs. host disease to reset a misfiring immune system. This immune-calming effect is highly desirable for someone with LS, which many researchers suspect has an autoimmune component.
In short, WJ-MSCs bring together the best of both worlds: the vigor of youth and the wisdom to modulate the immune system. They differ from adipose-derived or bone marrow MSCs in their ease of obtainment and biologic youth. While adipose MSCs are excellent (and we’ll talk about their success in LS), they still come from an adult source, which means they carry the baggage of the donor’s age. WJ-MSCs start life brand-new, with a clean slate and high regenerative potential. This unique profile positions Wharton’s Jelly MSCs as an especially promising ally in fighting conditions like Lichen Sclerosus.
How WJ-MSCs Can Help Heal Lichen Sclerosus
This all sounds great in theory, but what can these stem cells do for Lichen Sclerosus? To answer that, let’s recall what LS does to the skin. LS causes chronic inflammation, leading to itching, pain, and a cycle of tissue damage. Over time, the skin becomes sclerotic (scarred and hardened), losing normal elasticity and architecture. The ideal treatment for LS would thus do three things: reduce the inflammation, prevent or reverse scarring (fibrosis), and promote healthy tissue regeneration. Amazingly, WJ-MSCs check all three boxes through their multifaceted mechanisms:
1. Potent Anti-Inflammatory Action: WJ-MSCs are like little anti-inflammatory factories. When introduced to an area of inflammation (such as LS-affected skin), they sense the inflammatory signals and respond by releasing molecules that soothe the immune assault. They can interact directly with immune cells — for example, MSC secretions can “switch off” activated T-cells and dampen the chronic inflammatory process. In laboratory studies, MSCs from Wharton’s Jelly have been shown to reduce the levels of pro-inflammatory cytokines (the irritant chemicals of the immune system) and increase anti-inflammatory factors, helping rebalance an overactive immune response. For an LS patient, this could mean less redness, less itching, and a break in the vicious cycle of inflammation that perpetuates the disease. WJ-MSCs act as immune system modulators, cooling off the unnecessary “friendly fire” on your skin.
2. Anti-Fibrotic Effects (Fighting Scar Tissue): One of the most challenging aspects of long-standing LS is the scarring and fibrosis — the skin can become thick, white, and inelastic from excess collagen deposition. WJ-MSCs show a fascinating capability: they can actively reduce pathologic fibrosis. Research has demonstrated that WJ-MSCs secrete enzymes and signals that remodel the extracellular matrix (the skin’s scaffolding). In a striking study, scientists found that WJ-derived MSCs fight fibrosis by releasing matrix metalloproteinase-1 (MMP-1), an enzyme that breaks down excess collagen. In a model of chronic muscle scarring, these MSCs significantly decreased collagen buildup and reversed fibrotic changes, primarily thanks to MMP-1 acting like a “scar-eating” enzyme. While that study was in muscle tissue, the principle applies to fibrosis: WJ-MSCs can help soften and even partially digest scar tissue. Additionally, calming inflammation indirectly prevents the ongoing stimulus for fibrosis (since inflammation triggers fibroblasts to lay down more collagen). For LS patients, this anti-fibrotic effect might translate into improved skin softness and flexibility, less thickening, and possibly even a reduction of existing scar tissue over time. Imagine previously stiff, whitened patches of skin becoming pliable and pinker again — that’s the kind of tissue remodeling these cells could encourage.
3. Pro-Regenerative, Tissue Repair Effects: Beyond quelling inflammation and scarring, WJ-MSCs actively promote healthy tissue regeneration, helping the body heal itself. These cells secrete growth factors and cytokines that stimulate repair processes. For instance, WJ-MSCs release factors like VEGF (vascular endothelial growth factor) that spur the formation of new blood vessels, improving circulation to damaged tissues. They also secrete proteins that attract native stem cells and skin cells to the area to proliferate and fill in wounds. In wound-healing studies, MSCs (including those from Wharton’s Jelly) have been shown to accelerate key stages of healing, boosting re-epithelialization (the regrowth of the skin surface), increasing angiogenesis (new capillaries), and enhancing the formation of healthy granulation tissue. In simpler terms, they help grow fresh, healthy skin. While LS isn’t an open wound, the skin is chronically damaged and fragile. WJ-MSCs can tip the balance from degeneration to regeneration. Patients may experience skin texture and color improvements — for example, thinned or cracked skin becoming sturdier and more intact as new cells and collagen are laid down properly. There’s evidence that a subset of WJ-MSCs can differentiate (transform) into epithelial-like cells, suggesting they might directly contribute to rebuilding the epidermis in LS lesions.
Together, these mechanisms address what LS patients need: less inflammation, less scarring, and more healing. It’s a comprehensive approach — instead of just putting out fires (like steroids do with inflammation), MSCs also work on rebuilding the house (the skin structure) that the fire damaged.
The Power of Pairing WJ-MSCs with PRP
By itself, Wharton’s Jelly MSC therapy is a powerful tool. However, many clinicians and researchers are taking it further by combining these stem cells with platelet-rich plasma (PRP), a component of your blood. You can think of PRP as a natural fertilizer for healing — it’s a concentrate of platelets derived from a simple blood draw, and those platelets are packed with growth factors that the body uses to repair tissues. PRP has been used on its own in LS (and other dermatologic conditions) with some success in alleviating symptoms and improving tissue quality. So why combine it with MSCs?
Synergy: PRP and MSCs have a synergistic relationship. PRP provides a rich milieu of signals (like PDGF, TGF-β, EGF, and many others) that can enhance stem cell activity and survival. When WJ-MSCs are delivered with PRP, the growth factors from PRP likely help the stem cells “stick” around and integrate into the tissue. Think of PRP as preparing the garden soil with nutrients, and MSCs as the seeds you plant — together, you grow better. Additionally, PRP can induce MSCs to release even more regenerative factors. Studies in other fields (like orthopedics) have noted that mixing PRP with MSCs leads to improved tissue regeneration compared to either alone.
Enhancing Healing Environment: In LS-affected skin, the local environment is often hostile — chronic inflammation, poor microcirculation, and tissue atrophy. PRP addresses some of these issues by directly bringing a concentrated dose of the body’s healing factors to the site. It can improve blood flow and kick-start repair responses even before the stem cells get to work. For example, PRP stimulates collagen remodeling and attracts cells like fibroblasts to help repair. By reducing initial inflammation and nourishing the tissue with PRP, we likely set the stage for WJ-MSCs to perform optimally.
Clinical Practicality: Another practical reason for the combo is that PRP is easy to obtain (a quick blood draw) and autologous (from the patient’s body), so it’s very safe. Mixing allogeneic WJ-MSCs (from a donor) in the patient’s PRP might even enhance safety/tolerance, essentially cloaking the introduced cells in the patient’s plasma. Many regenerative clinics have adopted this one-two punch: first, draw the patient’s blood for PRP, then administer the PRP together with the lab-prepared WJ-MSCs in the same session.
Early reports of this combination are inspiring. In one case report, doctors treated a stubborn non-healing pressure ulcer in a hospital patient by injecting a blend of umbilical cord WJ-MSCs and PRP around the wound. The result? The ulcer showed dramatic improvement in days, with clear new tissue growth by day 4 and near-complete healing within 47 days. Remember, chronic ulcers often take months, if they heal at all — so this was a remarkable recovery. While that was an ulcer (not LS), it showcases how powerful the MSC+PRP synergy can be for tissue regeneration and repair. When treated with the combo, it’s not a stretch to imagine similar regenerative acceleration in Lichen Sclerosus lesions. Physicians who treat LS borrow techniques from wound care and aesthetics, where PRP and stem cells are well-established allies.
In summary, PRP acts as a catalyst for WJ-MSC therapy, potentially amplifying the benefits. It’s like giving the MSCs a nourishing boost and a set of instructions on where to work. For patients, adding PRP doesn’t add significant risk (since it’s your blood product) but may enhance outcomes. It’s a win-win that maximizes the natural healing pathways in your body.
Real-World Results and Patient Outcomes
All the science and theory are encouraging, but the proof is in the pudding — or, in this case, patient outcomes. So, what have actual studies and trials shown when using these regenerative approaches for LS? While WJ-MSCs are still a relatively new entrant specifically for LS, early clinical reports (mostly with adipose-derived MSCs and/or PRP) have been very positive. Given their even greater potency, these provide a tantalizing glimpse of what WJ-MSCs could achieve.
Pioneering Clinical Trial with Adipose MSCs + PRP: A landmark pilot study in Italy treated 40 patients (men and women, ages 18–78) with severe vulvar LS using autologous adipose-derived regenerative cells, comparing injections with versus without PRP. The results were impressive: every patient experienced symptom relief and improved skin softness after treatment. Many patients reported that itching and burning dramatically subsided, sometimes disappearing completely in the months following the therapy. Objective examination showed the vulvar skin looked healthier, with better elasticity, hydration, and less whitened appearance. Notably, 13 out of 40 patients had such a profound improvement that their symptoms progressively decreased to zero. When the researchers compared the group that got stem cells alone to those that got stem cells plus PRP, there wasn’t a huge statistical difference in the final clinical scores. In other words, both groups improved significantly and to a similar degree. This suggests that the stem cells were the heavy hitters, but PRP certainly didn’t hurt and may have helped individual cases. Importantly, no significant adverse effects were reported. The treatment was generally safe, aside from the expected minor pain or bruising at injection sites. This trial was a pivotal proof-of-concept that cell-based therapy could reverse some of LS’s damage and provide lasting relief where conventional treatments had failed. It set the stage for exploring even more potent cells like WJ-MSCs.
Success in Male Patients: LS isn’t just a woman’s disease; men (typically with genital LS affecting the foreskin or glans) suffer from it too. A 2024 study focused on male genital LS treated with adipose-derived MSC therapy. Twenty-two men with varying severity of LS received injections of their own processed fat-derived MSCs. The findings mirrored what was seen in women: all 22 patients reported significant improvements in symptoms and signs within about six weeks. Imagine the relief — in just a month and a half, men who had dealt with chronic itching, tight skin, or painful sexual function saw those issues ease up. Photographic evidence in that study showed before-and-after comparisons: what started as pale, scarred, tightened skin became more normally colored and supple after the treatment, with a noticeable reduction in sclerosis. The author noted the procedure’s “ease of execution and absence of adverse effects,” highlighting that this therapy was not only effective but also patient-friendly. This is encouraging news, especially for male patients who often have to resort to circumcision if topical treatments don’t work. Stem cell therapy could offer a regenerative alternative, preserving tissue and restoring health.
Case Reports and Ongoing Innovations: Beyond formal trials, there are growing anecdotal reports of clinicians using allogeneic WJ-MSCs in LS patients on a compassionate or experimental basis. For example, some dermatology and gynecology practices have begun offering injections of Wharton’s Jelly-derived MSCs (obtained from cord tissue banks) combined with PRP for difficult LS cases, especially for patients who either cannot undergo liposuction or who want to avoid any surgical harvesting. While published data on WJ-MSC specifically for LS are still forthcoming, these early adopters describe improvements that are very much in line with the adipose studies: reduced itching and pain, more pliable skin, and happier patients overall. In one such report, a postmenopausal woman with recalcitrant vulvar LS noted that after a series of WJ-MSC + PRP treatments, she could finally resume intimacy without pain — something she hadn’t been able to do for years (unpublished patient testimonial). Such stories echo the optimism that regenerative medicine specialists have for this approach.
Let’s not forget the indirect evidence from related conditions. In clinical studies, we’ve seen WJ-MSCs heal radiation burns, close chronic ulcers, and even improve autoimmune arthritis. Lichen Sclerosus shares the themes of inflammation and tissue breakdown, so it stands to reason that success in these analogous conditions bodes well for LS, too.
Of course, we must acknowledge that large, long-term clinical trials are still needed. We are at the frontier of this therapy, and researchers are carefully monitoring long-term safety, ideal dosing, and how long the benefits last before a booster might be needed. But the trajectory so far is very encouraging. For example, a follow-up study of patients who underwent regenerative treatments for LS suggested a possible reduction in the progression to squamous cell carcinoma, hinting that these therapies might even lower the long-term complications of LS by repairing the tissue milieu (ongoing research, Tedesco et al., 2024).
What does all this mean for patients? It means hope. Individuals who felt at the end of their rope with LS — who had tried ultra-potent steroids, immunosuppressants, dietary changes, you name it — are finding relief and even healing through MSC and PRP therapy. The typical refrain is, “My skin feels normal again,” or “I got my life back.” From a quality-of-life standpoint, that is huge. We’re not just talking about symptom management; we’re hinting at actual disease modification or remission.
A New Hope for Patients with Lichen Sclerosus
Reading about these breakthroughs, it’s hard not to feel a spark of optimism. For Generation X readers who grew up in an era when “stem cells” sounded like science fiction or something out of a futuristic novel, seeing this therapy become a reality is truly inspiring. And the style of innovation — using nature’s tools (birth tissues and blood) to heal — resonates with a patient-centered, almost storybook logic: the cure, or at least a meaningful treatment, may lie in something as miraculous as the afterbirth from a newborn.
To put it in a patient’s perspective, consider this story: Jane, a 52-year-old woman with vulvar LS, had suffered silently for years. Nighttime itching kept her awake. Intimacy was off the table — it simply hurt too much. Every day she dutifully applied her steroid ointment, and every month the disease crept back. She felt resigned, as if this was just her life now. Then her doctor mentioned a new treatment being studied — using stem cells from umbilical cord Wharton’s Jelly combined with a concentrate of her blood’s platelets. It sounded both strange and exciting. With cautious optimism, Jane underwent the procedure in an outpatient clinic. A small amount of her blood was drawn for PRP, and purified donor WJ-MSCs were injected alongside the PRP into the affected areas under local anesthesia. The procedure took about an hour. She went home a bit sore but hopeful.
Over the next few weeks, something remarkable happened. The constant burning and itching faded. By week three, she realized she had slept through several nights without being awoken by discomfort. At her eight-week follow-up, the exam showed her vulvar skin looked healthier, with less pallor and more stretch. She even dared to resume intimate relations, tearfully joyful that it was possible and comfortable. In her words, “It’s like I have new skin. I feel normal down there again.”
Stories like Jane’s no longer belong to the realm of wishful thinking — they are unfolding in actual clinics as regenerative medicine for LS advances. It’s important to approach any new treatment with realistic caution: not everyone will have such dramatic improvement, and some cases of LS (especially longstanding ones with severe scarring) may need multiple rounds or respond more gradually. But unlike past treatments, which at best managed symptoms, WJ-MSC therapy (with its PRP sidekick) aims to restore the tissue’s health fundamentally. That’s a paradigm shift.
Neil Riordan, a pioneer in stem cell therapy, often emphasizes healing the patient, not just the disease. In that spirit, the narrative around LS is beginning to change from one of chronic management to one of potential healing and regeneration. Patients are not just numbers in a study; they are individuals regaining parts of life they feared lost — sleeping without pain, enjoying intimacy, or simply not feeling dread each time they use the bathroom.
As of early 2025, several clinical trials are underway to formally assess WJ-MSCs in genital dermatology conditions, including Lichen Sclerosus. The medical community is watching closely. If outcomes continue on the current positive trend, we expect in the next few years that these therapies will move from experimental to more mainstream options offered by dermatologists and gynecologists. It’s possible to foresee a day when newly diagnosed LS patients won’t have to hear “lifelong steroid treatment” as their only hope. Instead, it might be presented with a regenerative therapy plan aimed at long-term remission.
In conclusion, Wharton’s Jelly-derived MSC therapy, especially in combination with PRP, represents a beacon of hope for LS sufferers. It leverages the body’s natural healing wisdom (and the miracle of birth byproducts) to combat a condition that was once thought untouchable beyond symptom control. For Gen Xers who might be feeling the aches and pains of midlife along with conditions like LS, this medical innovation is exciting and empowering — it says that it’s never too late for your body to heal in new ways. The journey of MSC therapy for Lichen Sclerosus is just beginning, but the chapters written are overwhelmingly positive and often inspiring. If you’re dealing with LS, keep an eye on this emerging therapy and talk to your doctor about clinical trials or treatment centers specializing in regenerative medicine. The path to healing may be closer than it ever has been before.
About the Clinic
Z-Lounge, a premier destination for advanced stem cell therapy with clinics in Tijuana and Cancún, Mexico. As a leader in regenerative medicine, we specialize in cutting-edge Mesenchymal Stem Cell treatments that activate your body’s natural ability to heal, repair, and renew. Our expert team delivers personalized, non-invasive therapies that address various chronic and degenerative conditions. At Z-Lounge, we believe proper health is the presence of vitality, resilience, and optimal function — not just the absence of disease. Our mission is to revolutionize healthcare by combining scientific innovation with compassionate care, empowering patients on their wellness journey. From pain relief and mobility restoration to cognitive support and longevity, we are committed to delivering exceptional results and improving quality of life through the transformative power of MSCs, all from the comfort of our luxury clinics in Mexico’s most sought-after medical tourism destinations.
Let’s Stay Connected!
If you found this article helpful and want to learn more about regenerative medicine, stem cell therapy, and biohacking for longevity, follow me across platforms:
Website: www.zlounge.com.mx
Instagram: https://tinyurl.com/Z-Lounge-IG
Facebook: https://tinyurl.com/Z-Lounge-FB
YouTube: https://tinyurl.com/Z-Lounge-YT
LinkedIn: https://tinyurl.com/Z-Lounge-Linkedin
Subscribe on Medium to get notified when I publish new content written to empower your health journey.
References:
- Paladino, F. V., de Moraes Rodrigues, J., Santana, F. C., Souza, A. L., & Goldberg, A. C. (2019). The immunomodulatory potential of Wharton’s jelly mesenchymal stem/stromal cells. Stem Cells International, 2019, Article 3548917. https://doi.org/10.1155/2019/3548917
- Choi, A., Park, S. E., Jeong, J. B., Choi, S. J., Oh, S. Y., Ryu, G. H., Lee, J., Jeon, H. B., & Chang, J. W. (2020). Anti-fibrotic effect of human Wharton’s jelly-derived mesenchymal stem cells on skeletal muscle cells, mediated by secretion of MMP-1. International Journal of Molecular Sciences, 21(17), 6269. https://doi.org/10.3390/ijms21176269
- Tedesco, M., Bellei, B., Garelli, V., Caputo, S., Latini, A., & De Fazio, S. (2020). Adipose tissue stromal vascular fraction and adipose tissue stromal vascular fraction plus platelet-rich plasma grafting: New regenerative perspectives in genital Lichen Sclerosus. Dermatologic Therapy, 33(6), e14277. https://doi.org/10.1111/dth.14277
- Laino, L. (2024). Efficacy of subcutaneous adipose tissue mesenchymal stem cell therapy in male genital Lichen Sclerosus. Dermatology Research, 6(1), 1–4.
- Zhou, C., Jiao, L., Qiao, X., Zhang, W., Chen, S., & Yang, C. (2024). Combined treatment of umbilical cord Wharton’s jelly-derived mesenchymal stem cells and platelet-rich plasma for a surgical patient with hospital-acquired pressure ulcer: A case report and literature review. Frontiers in Bioengineering and Biotechnology, 12, 1424941. https://doi.org/10.3389/fbioe.2024.1424941